Cara Pharma - TVRD Earnings per share for the last 12 months

Official company branding of Cara Therapeutics, Inc. (TVRD)

The market valuation dynamics for Cara Therapeutics Inc (TVRD) on the GURU.Markets platform, where the indicator stands at 67.50, reflect the current position of management as they pivot their strategy following setbacks with their lead drug candidate. Cara Therapeutics Inc develops kidney therapies while adhering to fundamental standards within its laboratories. Furthermore, the business invests in wastewater treatment and the safe processing of chemicals to minimize environmental impact.

TVRD: Cara Pharma Net earnings per share (EPS TTM) 02/11/2024 - 11/18/2026

caratherapeutics.com - analytical breakdowns and key metrics (TVRD)

- market price and analyst price targets:
Fundamental company valuation:TVRD - Cara Therapeutics, Inc.
Core merchandise of Cara Therapeutics Inc

This indicator serves as the baseline coordinate axis for assessing the twelve-month growth of earnings per share on a daily basis. The formula measures the rate of change in per-share income, determining the business's historical resilience to economic cycles. By analyzing the annual dynamics of the EPS TTM metric, the investor sees the current value of 67.50, reflecting a critical decline. Amidst workforce reductions and failed clinical trials at Cara Therapeutics Inc (TVRD), this metric confirms that the company is in a stage of deep survival crisis.